Company intelligence / Profile preview

Pleno Inc.

San Diego, California, United Statesplenoinc.com ↗

Ownership: Private
Employees: ~64
Development stage: Preclinical

Overview

Pleno has developed a multi-omic platform that can simultaneously analyze DNA, RNA, methylation structures, and proteins. The company is preparing for commercial launch of its RAPTOR instrument in 2025[4][5].

Therapeutic areas: OncologyWomen's HealthInfectious Diseases
Modalities: Multi-omics diagnostics (DNA, RNA, methylation, proteins)
Industry: Molecular Diagnostics

Partnerships

BioLegend (partnership for TotalSeq portfolio of antibodies)[5]

Beyond the preview

Go deeper on Pleno Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pleno Inc..

Explore the full profile